Lung Cancer in Patients With Lung Transplants

Espinosa, Dionisio; Baamonde, C.; Illana, J.; Arango, E.; Carrasco, Guadalupe; Moreno, Paula; Algar, Francisco Javier Algar; Álvarez, Antonio; Cerezo, Francisco; Santos, Francisco; Vaquero, José M.; Redel, Javier; Salvatierra, A.

doi:10.1016/j.transproceed.2012.07.067

Cited by 20 publications

(14 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2 separate studies, the incidence of these bronchogenic cancers in lung transplants was 2.4% in 290 transplant recipients [37] and 2.6% in 345 transplant recipients [38] . The average interval from transplantation to the development of lung cancer is 5 years.…”

Section: Cancers That Develop In the Transplantsmentioning

confidence: 96%

See 1 more Smart Citation

Assessment of Chimerism in Epithelial Cancers in Transplanted Patients

Lebœuf

Ratajczak²,

Verine³

et al. 2014

Pathobiology

View full text Add to dashboard Cite

and the recipient. The results of different studies address the cancers that develop in both recipients and in transplants. The presence of chimeric cells in these two types of cancer implies an exchange of progenitor/stem-cells between transplant and recipient, and the plasticity of these progenitor/stem-cells contributes to epithelial cancers. The presence of chimeric cells in concomitant cancers and preneoplastic lesions implies that the oncogenesis of these cancers progresses through a multistep process.

show abstract

Section: Cancers That Develop In the Transplantsmentioning

confidence: 96%

“…The average interval from transplantation to the development of lung cancer is 5 years. These cancers occurred in patients with a history of smoking [37,38] and are usually diagnosed at an advanced stage and have a poor outcome [37] .…”

Section: Cancers That Develop In the Transplantsmentioning

confidence: 99%

Assessment of Chimerism in Epithelial Cancers in Transplanted Patients

Lebœuf

Ratajczak²,

Verine³

et al. 2014

Pathobiology

View full text Add to dashboard Cite

show abstract

“…Referring to the study by Olland et al and our own literature search, 12 references (31,47,53,61,63,(66)(67)(68)(69)(70)(71)(72) were found reporting on primary lung cancer developing in the transplanted lung, most often after double-lung transplantation. The prevalence of bronchogenic carcinoma in the transplanted lung ranged from 0.3% to 0.4% (39).…”

Section: Primary Lung Cancer In the Allograftmentioning

confidence: 99%

Lung cancer: a rare indication for, but frequent complication after lung transplantation

Raemdonck¹,

Vos²,

Yserbyt³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Lung transplantation is an effective and safe therapy for carefully selected patients suffering from a variety of end-stage pulmonary diseases. Lung cancer negatively affects prognosis, particularly in patients who are no longer candidates for complete resection. Lung transplantation can be considered for carefully selected and well staged lung cancer patients with proven, lung-limited, multifocal, (minimally invasive) adenocarcinoma in situ (AIS) (previously called bronchioloalveolar cell carcinoma) causing respiratory failure. Despite a substantial risk of tumour recurrence (33-75%), lung transplantation may offer a survival benefit (50% at 5 years) with best palliation of their disease. Reports on lung transplantation for other low-grade malignancies are rare. Lung transplant candidates at higher risk for developing lung cancer [mainly previous smokers with chronic obstructive lung disease (COPD) and idiopathic pulmonary fibrosis (IPF) or older patients] should be thoroughly and repeatedly screened for lung cancer prior to listing, and preferably also during waiting list time if longer than 1 year, including the use of PET-CT scan and EBUS-assisted bronchoscopy in case of undefined, but suspicious pulmonary abnormalities. Double-lung transplantation should now replace single-lung transplantation in these high-risk patients because of a 6-9% prevalence of lung cancer developing in the remaining native lung. Patients with unexpected, early stage bronchial carcinoma in the explanted lung may have favourable survival without recurrence. Early PET-CT (at 3-6 months) following lung transplantation is advisable to detect early, subclinical disease progression. Donor lungs from (former) smokers should be well examined at retrieval. Suspicious nodules should be biopsied to avoid grafting cancer in the recipient. Close follow-up with regular visits and screening test in all recipients is needed because of the increased risk of developing a primary or secondary cancer in the allograft from either donor or recipient origin.

show abstract

“…11 However, recipient smoking has been linked with posttransplant lung cancer development in 1 series, with 1 of the patients affected having a diagnosis of CF. 12 Those investigators reported that 2.6% of recipients developed lung cancer. Additionally, there is a single case reported of donor-acquired small cell lung cancer following LTx in a CF patient whose donor was a former smoker.…”

Section: Introductionmentioning

confidence: 99%

Untitled

2015

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: The effect of prior cigarette use by lung transplant donors and recipients on posttransplant survival is poorly defined, especially in subjects with cystic fibrosis. We sought to determine if donor or recipient cigarette smoking is associated with differential postlung transplant outcomes in cystic fibrosis patients, including survival. Materials and Methods: The United Network for Organ Sharing database was searched to analyze a large sample of cystic fibrosis patients with a history of lung transplant. The primary endpoint of the study was overall survival after transplant based on either recipient or donor history of smoking cigarettes. Results: There was a significant decrease in survival for cystic fibrosis patients who received lungs from a donor with a history of smoking (P = .026), but no difference in survival for recipients with a personal history of smoking. Nearly 60% of subjects who received lungs from a smoking donor died during the study. Donor smoking history was correlated with survival in a univariate (HR 1.2, [1.04-1.3]), but not multivariate model. Donor smoking history also was associated with increased treatment for rejection within the first year after transplant (P = .005). Conclusions:More than 20 pack-year history of donor smoking may affect lung transplant outcomes (eg, survival and acute rejection) in patients with cystic fibrosis. Caution must be exercised when choosing suitable organ donors for cystic fibrosis patients requiring a lung transplant.

show abstract

Lung Cancer in Patients With Lung Transplants

Cited by 20 publications

References 6 publications

Assessment of Chimerism in Epithelial Cancers in Transplanted Patients

Assessment of Chimerism in Epithelial Cancers in Transplanted Patients

Lung cancer: a rare indication for, but frequent complication after lung transplantation

Untitled

Contact Info

Product

Resources

About